In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates▿

AUTOR(ES)

Adam, Heather J.

FONTE

American Society for Microbiology (ASM)

RESUMO

The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC90/range [μg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/≤0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC90/range [μg/ml]; Escherichia coli, 32/≤0.015 to ≥512; Klebsiella pneumoniae, 2/≤0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to ≥512; Pseudomonas aeruginosa, 32/≤0.015 to ≥512; Acinetobacter baumannii, 1/0.12 to 16).

Documentos Relacionados

• In Vitro Antibacterial Activities of DQ-113, a Potent Quinolone, against Clinical Isolates
• Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates▿
• In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria
• Quinolone Resistance in Staphylococci: Activities of New Nonfluorinated Quinolones against Molecular Targets in Whole Cells and Clinical Isolates
• In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections